We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

MINDRAY In-Vitro Diagnostics

As a global leader in in-vitro diagnostics, Mindray provides a wide range of efficient, reliable IVD solutions for la... read more Featured Products: More products

Download Mobile App




Quantitative Agglutination Determined on Automatic Hematology Analyzer

By LabMedica International staff writers
Posted on 16 Sep 2020
The currently available agglutination identification methods are slide methods and test tube methods. More...
Based on the distribution, uniformity and comprehensive changes of non-aggregated cells and agglutinating cells in the liquid, the agglutination degree and strength can be determined by the naked eye.

The results are subject to the subjective influence of the observers, and it has been shown that the amount of agglutination determined in the same sample by different people and the determination of the same sample by the same person at different times were significantly different, thus affecting the accuracy and reliability of the study.

Medical Laboratorians at the Dalian Medical University (Dalian, China) selected and diluted Type A serum to react with the type B cells and the normal saline group was used as the control group. A red blood cell (RBC) count was performed using an automatic hematology analyzer (Mindray, Shenzhen, China), after incubation in a warm bath for 30 minutes. The degree of agglutination on the glass slide was also recorded. A positive serum of antinuclear antibody (ANA) was collected and RBC agglutination between RBC-O and ANA positive serum was determined using the automatic hematology analyzer method.

The scientists reported that the relationship between the results from the automatic hematology analyzer and the agglutination strength using the glass slide method was determined and showed that there was a good linear relationship between the agglutination index (AGI) and serum antibody concentration. There was a significant difference between the serum of ANA positive patients and the normal control group. The stability test results showed a coefficient of variation (CV) < 10% when using the automatic hematology analyzer, indicating that the reproducibility of the test was good.

The investigators found that when normal human serum (control group) was mixed with red blood cells the value was lower than when mixed with normal saline (AGI). Furthermore, the analysis found that the AGI value was normally distributed, so they believe that healthy donors are likely to have a low level of resistance to RBC antibody. This shows that the automatic hematology analyzer can detect weak agglutination antibody in serum, but classical methods cannot observe this phenomenon.

The authors concluded that the automatic hematology analyzer can not only effectively detect the agglutination antibody in serum, but also provides a new tool for clinical application to detect agglutination with high sensitivity, and is quantitative, objective and accurate. The study has been available online since July 3, 2020 in the journal Clinica Chimica Acta.



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Unlike conventional molecular methods, VedaBio\'s CRISPR-based technology detects targets without requiring amplification (Photo courtesy of Veda Bio)

Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes

Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.